Latest news with #Invivyd
Yahoo
2 days ago
- Business
- Yahoo
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.4 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -200.00%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.14, delivering a surprise of -250%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Invivyd, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $11.79 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 23.96%. This compares to year-ago revenues of $2.26 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Invivyd, Inc. shares have added about 79% since the beginning of the year versus the S&P 500's gain of 10%. What's Next for Invivyd, Inc.? While Invivyd, Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Invivyd, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $20.6 million in revenues for the coming quarter and -$0.15 on $74.55 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Medtronic (MDT), another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended July 2025. The results are expected to be released on August 19. This medical device company is expected to post quarterly earnings of $1.23 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Medtronic's revenues are expected to be $8.37 billion, up 5.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Invivyd, Inc. (IVVD) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Mint
08-08-2025
- Health
- Mint
The race to find a measles treatment as infections surge
As a record number of people in the U.S. are sickened with measles, researchers are resurrecting the search for something long-deemed redundant: treatments for the viral disease. After the measles vaccine was introduced in the 1960s, cases of the disease plummeted. By 2000, federal officials had declared measles eliminated from the U.S. This success led to little interest in the development of treatments. But now, as vaccination rates fall and infections rise, scientists are racing to develop drugs they say could prevent or treat the disease in vulnerable and unvaccinated people. 'In America, we don't like being told what to do, but we like to have options for our medicine chest," said Marc Elia, chairman of the board of Invivyd, a Massachusetts-based drugmaker that started working on a monoclonal antibody for measles this spring. Scientists across the country including at biotechs Invivyd and Saravir Biopharma—and institutions such as Vanderbilt University Medical Center and Georgia State University—are in the early stages of measles-treatment development. The drugs are still a ways from becoming available to patients but could offer alternatives to people who are immunocompromised, don't respond to the measles vaccine or are vaccine skeptics. Some doctors and researchers warn that measles treatments could further drive the drop in vaccination. Nationally, 92.5% of kindergartners received the measles, mumps and rubella, or MMR, shot in the 2024-2025 school year, according to Centers for Disease Control and Prevention data. In 2019-2020, the vaccination rate was over 95%, which is the rate encouraged by health authorities to prevent community transmission of measles. More than 1,300 people, most of them unvaccinated, have been diagnosed with measles this year—a 33-year high. 'One of the motivations of getting the vaccine right now is that there are no treatments," said Dr. Joel Warsh, a pediatrician who says more research is needed into immunization safety. Still, Invivyd is betting its measles monoclonal antibody could help curb infections and outbreaks. Unlike the MMR vaccine, which is designed to train the body to make its own antibodies—proteins that help defeat specific pathogens—monoclonal antibodies are lab-made versions that can be delivered intravenously or as an injection and boost immunity immediately. Antibody treatments could treat someone who is sick or help prevent measles in people recently exposed to the virus. They could benefit newborns and immunocompromised people who can't be vaccinated, as well as the minority of people who don't respond to the vaccine or whose immunity has waned. The treatments could offer weeks or months of protection against measles, researchers said. 'Think of it like antivenom after a snake bite," said Erica Ollmann Saphire, chief executive of the La Jolla Institute for Immunology, whose lab is developing its own monoclonal antibodies for measles. 'Even people unsure about vaccines, if they are already sick with measles, getting an antibody treatment could be palatable." Saphire's lab has identified a few antibodies that have shown promise in animal tests. Invivyd said it hoped to have a drug candidate by the end of the year. At Vanderbilt University Medical Center, Dr. James Crowe, a pediatric infectious-disease specialist, has found success with a half-dozen antibodies that still need to be tested in people. In searching for a treatment, researchers have been forced to better understand measles, which Crowe said hadn't been as thoroughly studied as some other ailments because the vaccine had been so successful. The body's immune response to measles, for instance, hadn't been well understood. But he and other researchers now have a clearer picture of how measles antibodies work. Some block the virus from attaching to cells, while others interfere with a mechanism that allows the virus to fuse with cell membranes. Alternatives to vaccination could be especially appealing among some communities in Texas, where Dr. Ben Edwards practices family medicine and has treated hundreds of measles patients, he said. Many of them were from a Mennonite community hard-hit by a recent measles outbreak and where vaccination rates are low. 'They're going to want to look at the data though," he said. 'There's been a tremendous uptick in lack of trust in medicine." Edwards said he understands why many of his patients are skeptical of the MMR vaccine, which he said lacked adequate safety data. The MMR shot remains the best and only way to prevent measles, the CDC said. Multiple large-scale studies conducted over decades have proven the MMR vaccine to be very safe and effective, the agency said. Edwards said it makes sense to develop treatments—both drugs and alternative remedies—for measles so people have options. He said it was logical to think that more people would opt out of vaccination if effective treatments existed. Edwards, who had never treated a measles patient until this year, said he advised patients to take vitamin A supplements such as cod liver oil. He said he also treated about one-third of his measles patients with budesonide, an inhalable steroid medication used to treat asthma, to help alleviate respiratory problems. His approach attracted the attention of Health and Human Services Secretary Robert F. Kennedy Jr., who praised Edwards as an 'extraordinary" healer. Neither vitamin A supplements nor budesonide are considered measles treatments, said the Infectious Diseases Society of America, though budesonide can be used to treat complications from the illness. Some studies show that people with vitamin A deficiencies can get sicker from the virus, but there is no evidence that patients who aren't deficient will benefit from taking more of it, said John Lednicky, a microbiologist at the University of Florida. 'The typical American is not deficient," he said. 'And if you take too much, it will make you sick." Measles can cause severe acute disease and rarely death, but also 'immune amnesia," which causes the body to forget how to fight other infections, doctors said. Richard Plemper, a biomedical scientist at Georgia State University whose lab is developing an oral antiviral treatment for the virus family that includes measles, said he thinks people who want to get vaccinated will still do so, whether treatments are available or not. The antiviral he is working on, which is designed to block the ability of viruses including measles from replicating, has shown efficacy in animal experiments. But Plemper said he isn't sure how his lab will fund further research. Scheduled tests for the antiviral compound in dogs were canceled recently after National Institutes of Health funding was terminated. Saravir Biopharma, which was launched in July in collaboration with Columbia University to develop a measles monoclonal antibody, is banking on a continuing decline in vaccination rates to further fuel a need for measles treatments—and in turn, more investor interest. 'This is just the beginning," said Dr. Ron Moss, Saravir's CEO. 'I don't see public-health officials in this country turning around and saying everyone will need to get vaccinated in the next couple of years." Moss said Saravir's antibody treatment, which is designed to stop the measles virus from fusing with the body's cells, could be tested in people as soon as next year. Write to Dominique Mosbergen at
Yahoo
02-07-2025
- Health
- Yahoo
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID SPEAR Study Group collaborators Drs. Michael Peluso, Amy Proal, and David Putrino are key thought leaders in the clinical and translational biology of Long COVID and Post-Vaccination Syndrome Initial SPEAR clinical efforts to be aimed at rigorous, controlled assessment of monoclonal antibody safety, translational biology, and exploratory efficacy in relevant patient populations characterized by persistent virus or circulating SARS-CoV-2 spike protein WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that it has formed a best-in-class clinical and translational study group, the SPEAR Study Group, with leading investigators focused on the biology and clinical disease or injury associated with chronic exposure to SARS-CoV-2 virus or mRNA vaccine-mediated spike protein. The SPEAR Study Group will structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein monoclonal antibody (mAb) therapy in people suffering from Long COVID or Post-Vaccination Syndrome (PVS), conditions believed to be mediated by persistent viral reservoirs or circulating spike protein. Persistent SARS-CoV-2 spike protein has been identified in both populations, and both populations have overlapping manifestations of apparent clinical disease. As many as 5% or more of Americans have reported recent Long COVID symptoms, an extraordinary medical burden that will continue to evolve as infections continue in the SPEAR Study Group was initiated in response to a growing number of case reports and reported case series from across the U.S. suggesting meaningful symptom relief / remission of Long COVID following use of PEMGARDA® (pemivibart), a monoclonal antibody currently authorized by the U.S. Food and Drug Administration (FDA) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals. PEMGARDA is not authorized for the treatment of Long COVID. While these emerging reports are anecdotal and uncontrolled, they collectively support a longstanding, mechanistically plausible hypothesis: that prolonged exposure to pathogenic SARS-CoV-2 spike protein or other forms of persistent virus or viral material may drive disease in some patients, and that reducing this burden through monoclonal antibody therapy may offer a promising therapeutic approach worthy of rigorous clinical investigation. Clinical research to be planned by the SPEAR Study Group is critical to exploring disease biology and evaluating efficacy endpoints that can enable registrational studies if appropriate in the future. The SPEAR Study Group includes the following investigators and researchers who, along with Invivyd, will collaborate on the design and anticipated execution of relevant clinical trials: Michael Peluso, M.D., MHS, Assistant Professor of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco Amy Proal, Ph.D., Co-Founder and CEO, Polybio Research Foundation and Scientific Director, Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ('CoRE') David Putrino, Ph.D., Nash Family Director of the Mount Sinai Cohen Center for Recovery from Complex Chronic Diseases ('CoRE') and Professor, Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai. The SPEAR Study Group intends to launch collaborative, multi-center translational clinical research on Long COVID, including PVS, as soon as practicable, including use of next-generation monoclonal antibody candidates from Invivyd such as VYD2311. 'It is now clear from a growing body of high-quality, peer-reviewed research that persistent spike protein or viral reservoirs can be identified in a meaningful portion of people with Long COVID,' said Dr. Peluso. 'For the first time in years, there is a company with the capability to explore this space using active, broadly neutralizing monoclonal antibodies. This research marks an essential step toward understanding what may cause debilitating COVID-driven chronic disease, and we hope will lay the groundwork for future efficacy studies that could deliver real therapeutic options to patients who have waited far too long.' 'Long COVID is a pervasive, debilitating, and underappreciated public health challenge affecting millions of adults and children in the U.S., with no approved treatments,' said Marc Elia, Chairman of the Board at Invivyd. 'Monoclonal antibodies have already demonstrated efficacy in preventing acute COVID-19 infections and treating acute COVID-19 infections, including long-term infections, and emerging anecdotal reports suggest pemivibart may have potential in addressing symptoms in some Long COVID patients. We believe that monoclonal antibodies are key to managing the ongoing burden of endemic COVID-19 disease in all forms, and as previously disclosed, we will be meeting with the FDA early in 3Q to discuss rapid approval pathways for COVID-19 mAbs. Meanwhile, our formation of the SPEAR Study Group is a critical step toward potentially unlocking a Long COVID treatment opportunity for patients in need by generating data needed to inform future studies and potential regulatory pathways. We look forward to sharing future milestones as we advance this important initiative.' About PEMGARDA PEMGARDA® (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd's investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1, XEC and LP.8.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells. PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. PEMGARDA is not authorized for use for treatment of COVID-19, treatment of Long COVID, or post-exposure prophylaxis of COVID-19. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccinations, should receive COVID-19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse reactions included systemic infusion-related reactions and hypersensitivity reactions, local infusion site reactions, and infusion site infiltration or extravasation. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning. To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Further, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges. Additionally, certain SARS-CoV-2 viral variants may emerge that have substantially reduced susceptibility to PEMGARDA, and PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants. The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner. PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90%, based on available information including variant susceptibility to PEMGARDA and national variant frequencies. About VYD2311 VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration. VYD2311 was engineered using Invivyd's proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. VYD2311 leverages the same antibody backbone as pemivibart, Invivyd's investigational mAb granted emergency use authorization in the U.S. for the pre-exposure prophylaxis (PrEP) of symptomatic COVID-19 in certain immunocompromised patients, and adintrevimab, Invivyd's investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit to learn more. Trademarks are the property of their respective owners. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'could,' 'expects,' 'estimates,' 'intends,' 'potential,' 'predicts,' 'projects,' and 'future' or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, expectations regarding the SPEAR Study Group and its anticipated goals; the plans of the SPEAR Study Group to structure and guide anticipated clinical trials evaluating the effects of broadly neutralizing anti-SARS-CoV-2 spike protein mAb therapy in people suffering from Long COVID or PVS; expectations regarding Long COVID prevalence and burden in the U.S.; statements about the potential of mAb therapy to offer a therapeutic approach to Long COVID; expectations regarding the capability of Invivyd to explore the Long COVID space; whether pemivibart may have potential in addressing symptoms in some Long COVID patients; the potential of the SPEAR Study Group research to lay groundwork for future efficacy studies; the company's expectation to share future milestones regarding the SPEAR Study Group initiative; expectations regarding engagement between Invivyd and the FDA; the potential of PEMGARDA as a mAb for pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents who have moderate-to-severe immune compromise; the potential of VYD2311 as a novel mAb candidate; the company's devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company's forward-looking statements and you should not place undue reliance on the company's forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress and results of the SPEAR Study Group, and the company's discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company's product candidates based on neutralizing activity in nonclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitope that pemivibart and VYD2311 targets remains structurally intact; whether the company's product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; whether mAb therapy is able to offer a therapeutic approach to Long COVID; the ability to gain alignment with the applicable regulatory authorities on clinical trial designs and regulatory pathways for COVID-19 mAbs, and the timing thereof; changes in the regulatory environment; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; future clinical trial site activation or enrollment rates; how long the EUA granted by the FDA for PEMGARDA will remain in effect and whether the EUA is revised or revoked by the FDA; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; changes in expected or existing competition; the company's reliance on third parties; complexities of manufacturing mAb therapies; macroeconomic and political uncertainties; the company's ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each filed with the Securities and Exchange Commission (SEC), and in the company's other filings with the SEC, and in its future reports to be filed with the SEC and available at Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. Contacts: Media Relations(781) 208-1747media@ Investor Relations(781) 208-1747investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31-05-2025
- Business
- Yahoo
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall
On Wednesday, H.C. Wainwright analyst Matthew Hedberg adjusted the price target on Invivyd Inc. (NASDAQ:IVVD) from $10 to $5, while maintaining a Buy rating. This revision follows a revenue shortfall in Q1 2025. Despite this, H.C. Wainwright believes that Invivyd is transitioning from a company solely focused on COVID-19 to a broader antibody-based infectious disease platform. A researcher examining a microscope in a laboratory to further their clinical-stage discovery. The firm also noted early signs of operational stabilization and pipeline expansion emerging in Q2 2025. Invivyd reported Q1 PEMGARDA net product revenue of $11.3 million, which was a decrease from $13.8 million sequentially. This decline was attributed to a planned transition from a contracted to an internalized sales force in January and February. However, the company has observed a re-acceleration of PEMGARDA revenue in Q2 2025 to date, with strong reported revenues, including record commercial days and weeks. Despite these positive signs, Invivyd faced a setback in February when the FDA declined its application for expanded Emergency Use Authorization/EUA of PEMGARDA to include treatment for active mild to moderate COVID-19 in immunocompromised individuals due to insufficient assurance of clinical benefit. Invivyd is now expanding its pipeline to include discovery programs against new viral targets, aiming to identify best-in-class medicines for diseases beyond COVID-19, such as RSV and measles. Invivyd Inc. (NASDAQ:IVVD) is a biopharmaceutical company that discovers, develops, and commercializes antibody-based solutions for infectious diseases in the US. While we acknowledge the potential of IVVD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IVVD and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall
On Wednesday, H.C. Wainwright analyst Matthew Hedberg adjusted the price target on Invivyd Inc. (NASDAQ:IVVD) from $10 to $5, while maintaining a Buy rating. This revision follows a revenue shortfall in Q1 2025. Despite this, H.C. Wainwright believes that Invivyd is transitioning from a company solely focused on COVID-19 to a broader antibody-based infectious disease platform. A researcher examining a microscope in a laboratory to further their clinical-stage discovery. The firm also noted early signs of operational stabilization and pipeline expansion emerging in Q2 2025. Invivyd reported Q1 PEMGARDA net product revenue of $11.3 million, which was a decrease from $13.8 million sequentially. This decline was attributed to a planned transition from a contracted to an internalized sales force in January and February. However, the company has observed a re-acceleration of PEMGARDA revenue in Q2 2025 to date, with strong reported revenues, including record commercial days and weeks. Despite these positive signs, Invivyd faced a setback in February when the FDA declined its application for expanded Emergency Use Authorization/EUA of PEMGARDA to include treatment for active mild to moderate COVID-19 in immunocompromised individuals due to insufficient assurance of clinical benefit. Invivyd is now expanding its pipeline to include discovery programs against new viral targets, aiming to identify best-in-class medicines for diseases beyond COVID-19, such as RSV and measles. Invivyd Inc. (NASDAQ:IVVD) is a biopharmaceutical company that discovers, develops, and commercializes antibody-based solutions for infectious diseases in the US. While we acknowledge the potential of IVVD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IVVD and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
